Safe Orthopaedics announces CE mark for Sycamore
May 24, 2021 02:34 ET | Source: Safe Orthopaedics Safe Orthopaedics Éragny, FRANCE
Very dynamic market segment
Worldwide commercialization expected in 2022
Éragny-sur-Oise, France, On May 24, 2021 à 8:35 CET – Safe Orthopaedics (FR0013467123 – ALSAF), a holding of the Safe Group (composed of Safe Orthopaedics, a company specializing in the design, manufacturing and marketing of single-use technologies for spinal surgeries, and Safe Medical (Ex-LCI medical), integrated subcontractor for orthopedic medical devices, today announces the CE mark for Sycamore, a new treatment for the management of patients with one or more osteoporotic fractures.
Osteoporotic fracture is a global clinical issue. Driven by the aging population and the dynamic lifestyle of those 50 years and older, the number of vertebral fractures has increased significantly over the past two decades.
Safe orthopaedics : Marquage CE pour Sycamore tradingsat.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tradingsat.com Daily Mail and Mail on Sunday newspapers.
Alpha Blue Ocean : & Europlasma, a Leader in Emissions Control Solutions, Have Signed a Seven-year Financing Agreement for a Total Commitment of 100-Million-Euro marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
0%
On the first quarter 2021, the sale of the group were €1,077k, stable compared to the first quarter of 2020, despite the sanitary crisis that impacted the whole quarter, contrary to the previous year.
Despite the restriction measures and the postponement of surgeries in France, United Kingdom and Germany, direct annual sales grew by 55%, with heterogeneous performances depending on the country: while the United Kingdom showed a 69% contraction in sales due to strict confinement in the first quarter, Germany showed a growth of 121% despite a constrained health context. The growth in direct sales is explained on one hand by the market penetration of Sterispine
Investegate announcements from Safe Orthopaedics, Safe Group and the american company SpineUp announce the signature of a technological co-development agreement